Trinity Biotech (TRIB)
by Zacks Equity ResearchMarch 09, 2011 | Comments : 0 Recommended this article: (0)
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at firstname.lastname@example.org or call 800-767-3771 ext. 9339.
Development of several new POC tests is ongoing, the fruits of which should be realized in 2012. TRIB has also just announced a share buyback program and dividend.
Management has a recent history of underpromising and overdelivering. We are maintaining our Outperform rating. Our price target has moved from $9.90 to $10.80.
Read the full reports :
Please login to Zacks.com or register to post a comment.